93/100 A+ · Low risk
No major risk flags in the public sources we cover Indicative TraceComp estimate from public sources — an automated indicator, not a credit decision, a completed due-diligence check, or a guarantee. Verify against the official register.

ℹ️ No matches surfaced in the limited public sources we cover (sanctions, screening, insolvency, control). This is an automated indicator — not an exhaustive check, a credit decision, or a guarantee, and absence of a match does not mean none exists. Verify against the official register.

Think this is wrong? This is an automated estimate — request a human review or correction.

VšĮ studija "Versus"

Active Viešoji įstaiga Active for 21 years

Viešoji įstaiga · RC 300039369 · Active since 2004

A+

Overview

VšĮ studija "Versus" is a viešoji įstaiga registered in Lithuania, since 2004. With reported revenue of 56K EUR in 2025. Its TraceComp score of 93 (A+) indicates solid fundamentals and low apparent risk. With 21 years of operations, the company has an established track record in its market.

Company Information

Registration Number
300039369
Legal Form
Viešoji įstaiga
Registered
2004-07-08

Financial Profile

Latest filed accounts: FY 2025

Revenue (2025) 56,498 EUR
Net Income 7,234 EUR
Total Assets 31,546 EUR
Altman Z 15.74 safe

Multi-year financials & ratios

5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Risk Signals

No adverse legal events have been recorded for this company.

  • Revenue up 585% year-on-year
  • Profitable: positive net income in FY 2025
  • Altman Z-Score in the safe zone

Data Sources & Freshness

Data sourced from: bulk register.